Atara Biotherapeutics (ATRA) Q4 2025 earnings summary

Executive summary

• Achieved significant operational efficiencies and extended cash runway through year-end 2026.

• Focused on cost streamlining and supporting regulatory efforts for tabelecleucel in the U.S.

• Scheduled a Type A FDA meeting to address regulatory concerns for tabelecleucel.

Financial highlights

• Cash, cash equivalents, and short-term investments were $8.5 million as of December 31, 2025, down from $42.5 million a year earlier.

• Net cash used in operating activities was $5.7 million for Q4 and $50.9 million for FY 2025, both improved from 2024.

• Reported net income of $32.7 million for FY 2025, compared to a net loss of $85.4 million in 2024.

• Commercialization revenues were $120.8 million in 2025, down from $128.9 million in 2024.

• Total costs and operating expenses for FY 2025 were $84.9 million, significantly reduced from $212.4 million in 2024.

Outlook and guidance

• Operating expenses expected to decline further in 2026 due to cost-reduction initiatives.

• Cash position, combined with recent ATM proceeds and efficiencies, expected to fund operations through year-end 2026.